Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals' (NASDAQ:APLS) proposed treatment for ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2024 financial results and business highlights. “We have continued to execute well and progress our programs over the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)’s two primary revenue generating treatments EMPAVELI and SYFOVRE are primarily targeted towards people with eye diseases. The firm is also trying to ...

Aug. 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... well and progress our programs over the past six months. SYFOVRE delivered strong growth and is reaching more people living with ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)'s two primary revenue generating treatments EMPAVELI and SYFOVRE are primarily targeted towards people with eye diseases. The firm is also trying to expand ...